Klas Bergenheim

1.1k total citations
50 papers, 851 citations indexed

About

Klas Bergenheim is a scholar working on Endocrinology, Diabetes and Metabolism, Economics and Econometrics and Molecular Biology. According to data from OpenAlex, Klas Bergenheim has authored 50 papers receiving a total of 851 indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Endocrinology, Diabetes and Metabolism, 10 papers in Economics and Econometrics and 9 papers in Molecular Biology. Recurrent topics in Klas Bergenheim's work include Diabetes Treatment and Management (33 papers), Diabetes Management and Research (25 papers) and Health Systems, Economic Evaluations, Quality of Life (10 papers). Klas Bergenheim is often cited by papers focused on Diabetes Treatment and Management (33 papers), Diabetes Management and Research (25 papers) and Health Systems, Economic Evaluations, Quality of Life (10 papers). Klas Bergenheim collaborates with scholars based in Sweden, United Kingdom and United States. Klas Bergenheim's co-authors include Phil McEwan, Marc Evans, Hayley Bennett, P McEwan, John R. Peters, Oliver Darlington, Craig J. Currie, John J.V. McMurray, Martin Henriksson and Ola Granström and has published in prestigious journals such as PLoS ONE, Alimentary Pharmacology & Therapeutics and Clinical Journal of the American Society of Nephrology.

In The Last Decade

Klas Bergenheim

48 papers receiving 833 citations

Peers

Klas Bergenheim
Jetty A. Overbeek Netherlands
Annpey Pong United States
Lorin M Bachmann United States
V. Foos United Kingdom
Mats Bojestig Sweden
Elizabeth Marrett United States
Katy G. Wilkens United States
Jan Stålhammar Sweden
Janice D. Nunnelee United States
Stefania Saragoni Italy
Jetty A. Overbeek Netherlands
Klas Bergenheim
Citations per year, relative to Klas Bergenheim Klas Bergenheim (= 1×) peers Jetty A. Overbeek

Countries citing papers authored by Klas Bergenheim

Since Specialization
Citations

This map shows the geographic impact of Klas Bergenheim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Klas Bergenheim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Klas Bergenheim more than expected).

Fields of papers citing papers by Klas Bergenheim

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Klas Bergenheim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Klas Bergenheim. The network helps show where Klas Bergenheim may publish in the future.

Co-authorship network of co-authors of Klas Bergenheim

This figure shows the co-authorship network connecting the top 25 collaborators of Klas Bergenheim. A scholar is included among the top collaborators of Klas Bergenheim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Klas Bergenheim. Klas Bergenheim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
McEwan, Phil, Oliver Darlington, John J.V. McMurray, et al.. (2020). Cost-Effectiveness of Dapagliflozin as a Treatment for Heart Failure with Reduced Ejection Fraction: A Multinational Health-Economic Analysis of DAPA-HF. European Journal of Heart Failure. 22(11). 2147–2156. 96 indexed citations
4.
5.
Henriksson, Martin, et al.. (2016). A Systematic Review of Cost-Effectiveness Models in Type 1 Diabetes Mellitus. PharmacoEconomics. 34(6). 569–585. 29 indexed citations
6.
Henriksson, Martin, et al.. (2015). A Systematic Review of Cost-Effectiveness Models in Type 1 Diabetes Mellitus. Value in Health. 18(7). A607–A607. 13 indexed citations
7.
Ward, Thomas, et al.. (2015). Validation of the UKPDS 82 risk equations within the Cardiff Diabetes Model. Cost Effectiveness and Resource Allocation. 13(1). 12–12. 34 indexed citations
8.
McEwan, Phil, Hayley Bennett, Thomas Ward, & Klas Bergenheim. (2014). Refitting of the UKPDS 68 Risk Equations to Contemporary Routine Clinical Practice Data in the UK. PharmacoEconomics. 33(2). 149–161. 18 indexed citations
9.
Bennett, Hayley, Phil McEwan, Klas Bergenheim, & Jason Gordon. (2014). Assessment of Unmet Clinical Need in Type 2 Diabetic Patients on Conventional Therapy in the UK. Diabetes Therapy. 5(2). 567–578. 9 indexed citations
10.
McEwan, Phil, Tom Ward, Hayley Bennett, & Klas Bergenheim. (2014). Comparing the Event Prediction Capability of the Ukpds68 and Hong Kong Diabetes Risk Equations within A Type 2 Diabetes Simulation Model. Value in Health. 17(7). A729–A730. 1 indexed citations
11.
McEwan, P, Hayley Bennett, Thomas Ward, & Klas Bergenheim. (2014). Comparing the Use of Patient-Level Data to An Average Patient Profile Within a Type 2 Diabetes Simulation Model. Value in Health. 17(7). A546–A546. 1 indexed citations
12.
Bergenheim, Klas, et al.. (2013). Cost-Effectiveness of Dapagliflozin as Add-On to Insulin for the Treatment of Type 2 Diabetes in the Netherlands. Value in Health. 16(7). A441–A441. 1 indexed citations
13.
Bergenheim, Klas, Susan Grandy, & Gail Wygant. (2013). Cost of Achieving Relevant Composite Endpoint of HbA1c<7%, No Hypoglycaemia and Weight Loss of ≥3% in a 52 Week Post-Hoc Analysis of Dapagliflozin Versus Glipizide. Value in Health. 16(7). A439–A439. 1 indexed citations
14.
15.
Bergenheim, Klas, et al.. (2012). Cost Effectiveness of Saxagliptin and Metformin versus Sulfonylurea and Metformin in the Treatment of Type 2 Diabetes Mellitus in Germany. Clinical Drug Investigation. 32(3). 189–202. 37 indexed citations
16.
Juarez-Garcia, A., et al.. (2012). PDB53 Cost-Effectiveness of Saxagliptin (Onglyza®) in Type 2 Diabetes in South Africa. Value in Health. 15(4). A180–A180. 1 indexed citations
17.
Granström, Ola, Klas Bergenheim, Phil McEwan, Karin Sennfält, & Martin Henriksson. (2011). Cost-effectiveness of saxagliptin (Onglyza®) in type 2 diabetes in Sweden. Primary care diabetes. 6(2). 127–136. 39 indexed citations
18.
McEwan, Phil, et al.. (2010). Assessing the Relationship between Computational Speed and Precision. PharmacoEconomics. 28(8). 665–674. 23 indexed citations
19.
Söderström, Lars, et al.. (2000). Äldreomsorgens finansiering - Varför äldrevårdsförsäkring?. Lund University Publications (Lund University). 1 indexed citations
20.
Bergenheim, Klas, et al.. (1998). The Market for Pharmaceuticals. PubMed. 7. 187–208. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jetty A. Overbeek Breakdown of academic impact, for papers by Annpey Pong Breakdown of academic impact, for papers by Lorin M Bachmann Breakdown of academic impact, for papers by V. Foos Breakdown of academic impact, for papers by Mats Bojestig Breakdown of academic impact, for papers by Elizabeth Marrett Breakdown of academic impact, for papers by Katy G. Wilkens Breakdown of academic impact, for papers by Jan Stålhammar Breakdown of academic impact, for papers by Janice D. Nunnelee Breakdown of academic impact, for papers by Stefania Saragoni
Rankless by CCL
2026